BACKGROUND AND PURPOSE: Morphine is an antagonist at 5-HT(3) A receptors. 5-HT(3) and opioid receptors are expressed in many of the same neuronal pathways where they modulate gut motility, pain and reinforcement. There is increasing interest in the 5-HT3B subunit, which confers altered pharmacology to 5-HT(3) receptors. We investigated the mechanisms of inhibition by morphine of 5-HT(3) receptors and the influence of the 5-HT3B subunit. EXPERIMENTAL APPROACH: 5-HT-evoked currents were recorded from voltage-clamped HEK293 cells expressing human 5-HT3A subunits alone or in combination with 5-HT3B subunits. The affinity of morphine for the orthosteric site of 5-HT(3) A or 5-HT(3) AB receptors was assessed using radioligand binding with the antagonist [(3) H]GR65630. KEY RESULTS: When pre-applied, morphine potently inhibited 5-HT-evoked currents mediated by 5-HT(3) A receptors. The 5-HT3B subunit reduced the potency of morphine fourfold and increased the rates of inhibition and recovery. Inhibition by pre-applied morphine was insurmountable by 5-HT, was voltage-independent and occurred through a site outside the second membrane-spanning domain. When applied simultaneously with 5-HT, morphine caused a lower potency, surmountable inhibition of 5-HT(3) A and 5-HT(3) AB receptors. Morphine also fully displaced [(3) H]GR65630 from 5-HT(3) A and 5-HT(3) AB receptors with similar potency. CONCLUSIONS AND IMPLICATIONS: These findings suggest that morphine has two sites of action, a low-affinity, competitive site and a high-affinity, non-competitive site that is not available when the channel is activated. The affinity of morphine for the latter is reduced by the 5-HT3B subunit. Our results reveal that morphine causes a high-affinity, insurmountable and subunit-dependent inhibition of human 5-HT(3) receptors.
BACKGROUND AND PURPOSE:Morphine is an antagonist at 5-HT(3) A receptors. 5-HT(3) and opioid receptors are expressed in many of the same neuronal pathways where they modulate gut motility, pain and reinforcement. There is increasing interest in the 5-HT3B subunit, which confers altered pharmacology to 5-HT(3) receptors. We investigated the mechanisms of inhibition by morphine of 5-HT(3) receptors and the influence of the 5-HT3B subunit. EXPERIMENTAL APPROACH: 5-HT-evoked currents were recorded from voltage-clamped HEK293 cells expressing human5-HT3A subunits alone or in combination with 5-HT3B subunits. The affinity of morphine for the orthosteric site of 5-HT(3) A or 5-HT(3) AB receptors was assessed using radioligand binding with the antagonist [(3) H]GR65630. KEY RESULTS: When pre-applied, morphine potently inhibited 5-HT-evoked currents mediated by 5-HT(3) A receptors. The 5-HT3B subunit reduced the potency of morphine fourfold and increased the rates of inhibition and recovery. Inhibition by pre-applied morphine was insurmountable by 5-HT, was voltage-independent and occurred through a site outside the second membrane-spanning domain. When applied simultaneously with 5-HT, morphine caused a lower potency, surmountable inhibition of 5-HT(3) A and 5-HT(3) AB receptors. Morphine also fully displaced [(3) H]GR65630 from 5-HT(3) A and 5-HT(3) AB receptors with similar potency. CONCLUSIONS AND IMPLICATIONS: These findings suggest that morphine has two sites of action, a low-affinity, competitive site and a high-affinity, non-competitive site that is not available when the channel is activated. The affinity of morphine for the latter is reduced by the 5-HT3B subunit. Our results reveal that morphine causes a high-affinity, insurmountable and subunit-dependent inhibition of human 5-HT(3) receptors.
Authors: C A Brady; I M Stanford; I Ali; L Lin; J M Williams; A E Dubin; A G Hope; N M Barnes Journal: Neuropharmacology Date: 2001-08 Impact factor: 5.250
Authors: Ran Zhang; Xiaofei Wen; Julius Militante; Brent Hester; Heather E Rhubottom; Hongwei Sun; Nancy J Leidenheimer; Dong Yan; Michael M White; Tina K Machu Journal: Biochemistry Date: 2007-02-06 Impact factor: 3.162
Authors: Catherine A Brady; Terri J Dover; Andrew N Massoura; Alesandra P Princivalle; Anthony G Hope; Nicholas M Barnes Journal: Neuropharmacology Date: 2007-01-21 Impact factor: 5.250
Authors: Maria Wittmann; I Peters; T Schaaf; H C Wartenberg; S Wirz; J Nadstawek; B W Urban; M Barann Journal: Anesth Analg Date: 2006-09 Impact factor: 5.108
Authors: Karen Krzywkowski; Anders A Jensen; Christopher N Connolly; Hans Bräuner-Osborne Journal: Pharmacogenet Genomics Date: 2007-04 Impact factor: 2.089
Authors: Jane E Carland; Michelle A Cooper; Matthew R Livesey; Tim G Hales; John A Peters; Jeremy J Lambert Journal: J Biol Chem Date: 2013-09-12 Impact factor: 5.157